Login to Your Account



As Aastrom Falters, ReNeuron Advances Its CLI Cell Therapy

By Cormac Sheridan
Staff Writer

Wednesday, April 3, 2013
ReNeuron plc is planning to move its stem cell therapy ReN001 into a Phase I trial in critical limb ischemia (CLI), just as Aastrom Biosciences Inc., an erstwhile leader in the field, is stepping away from the fray.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription